In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Pacira BioSciences Inc (NASDAQ: PCRX) was $23.17 for the day, up 0.04% from the previous closing price of $23.16. In other words, the price has increased by $0.04 from its previous closing price. On the day, 0.83 million shares were traded. PCRX stock price reached its highest trading level at $23.97 during the session, while it also had its lowest trading level at $23.004.
Ratios:
Our analysis of PCRX’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.03. For the most recent quarter (mrq), Quick Ratio is recorded 3.78 and its Current Ratio is at 5.26. In the meantime, Its Debt-to-Equity ratio is 0.58 whereas as Long-Term Debt/Eq ratio is at 0.57.
On July 25, 2025, Truist Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $30. Truist Upgraded its Sell to Hold on January 30, 2025, whereas the target price for the stock was revised from $8 to $25.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 17 ’25 when SLONIN JONATHAN sold 3,960 shares for $24.09 per share. The transaction valued at 95,396 led to the insider holds 178,367 shares of the business.
SLONIN JONATHAN bought 3,960 shares of PCRX for $95,396 on Nov 17 ’25. On Nov 10 ’25, another insider, Cross Shawn, who serves as the Chief Financial Officer of the company, sold 12,060 shares for $22.09 each. As a result, the insider received 266,405 and left with 56,250 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCRX now has a Market Capitalization of 1041091136 and an Enterprise Value of 1175776896. As of this moment, Pacira’s Price-to-Earnings (P/E) ratio for their current fiscal year is 51.94, and their Forward P/E ratio for the next fiscal year is 6.88. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 9.32. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.39 while its Price-to-Book (P/B) ratio in mrq is 1.37. Its current Enterprise Value per Revenue stands at 1.64 whereas that against EBITDA is 7.809.
Stock Price History:
The Beta on a monthly basis for PCRX is 0.22, which has changed by 0.39182687 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, PCRX has reached a high of $27.64, while it has fallen to a 52-week low of $16.29. The 50-Day Moving Average of the stock is -1.35%, while the 200-Day Moving Average is calculated to be -5.10%.
Shares Statistics:
PCRX traded an average of 633.05K shares per day over the past three months and 681630 shares per day over the past ten days. A total of 42.97M shares are outstanding, with a floating share count of 42.05M. Insiders hold about 2.27% of the company’s shares, while institutions hold 114.16% stake in the company. Shares short for PCRX as of 1763078400 were 7276394 with a Short Ratio of 11.50, compared to 1760486400 on 5946077. Therefore, it implies a Short% of Shares Outstanding of 7276394 and a Short% of Float of 24.740000000000002.
Earnings Estimates
The market rating for Pacira BioSciences Inc (PCRX) is a result of the insights provided by 7.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.76, with high estimates of $0.81 and low estimates of $0.72.
Analysts are recommending an EPS of between $3.05 and $2.87 for the fiscal current year, implying an average EPS of $2.96. EPS for the following year is $3.37, with 7.0 analysts recommending between $3.61 and $3.1.
Revenue Estimates
It is expected that $90B in revenue will be generated in . The current quarter, according to 7 analysts. It ranges from a high estimate of $203.2M to a low estimate of $195.15M. As of . The current estimate, Pacira BioSciences Inc’s year-ago sales were $187.25MFor the next quarter, 7 analysts are estimating revenue of $186.87M. There is a high estimate of $190.05M for the next quarter, whereas the lowest estimate is $183.69M.
A total of 7 analysts have provided revenue estimates for PCRX’s current fiscal year. The highest revenue estimate was $732.7M, while the lowest revenue estimate was $724.68M, resulting in an average revenue estimate of $730.12M. In the same quarter a year ago, actual revenue was $700.97MBased on 7 analysts’ estimates, the company’s revenue will be $796.58M in the next fiscal year. The high estimate is $811.2M and the low estimate is $774.76M.
